Morepen Laboratories Submits First US ANDA for Sitagliptin Tablets in Three Strengths
Morepen Laboratories has submitted its first Abbreviated New Drug Application (ANDA) to the U.S. FDA for Sitagliptin Tablets in 25 mg, 50 mg, and 100 mg strengths. This submission marks an expansion of Morepen's contract development and manufacturing capabilities, integrating formulation development, analytical validation, impurity control, and regulatory filing under GMP standards. The company anticipates FDA approval and commercial supply within 24-36 months, subject to regulatory review and patent considerations. Sitagliptin is used to treat Type 2 diabetes, with significant market potential.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (58/100). Lens Score 35/100.
Outlets measured: thetribune, freepressjournal, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 28 Sept, 03:57 am. Other outlets followed.